Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
AdComnegativeDeramiocelNegative
AI Analysis
Summary
Capricor Therapeutics' Deramiocel received a negative vote from the FDA's Cellular, Tissue and Gene Therapies Advisory Committee, with the committee voting that available evidence does not support the drug's effectiveness for cardiomyopathy treatment in DMD patients. The advisory committee vote is non-binding.
Outcome Details
FDA Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support effectiveness (3 for, 9 against, 0 abstain). Committee vote is non-binding.
Importance:8/10
Sentiment:
-0.95
FDA AdComcell therapyrare diseasecardiomyopathyDMDregulatory setback
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 30, 2026 1:30 PM